http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2268064-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate | 2005-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_661ff8c5b71907e7c0222bd91de8a3dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e52edf7c420a0f2e02592395b942de02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e2b056e01aa7e434e0c5d44e3e4b447 |
| publicationDate | 2006-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2268064-C1 |
| titleOfInvention | Method for treating acute cerebral stroke cases |
| abstract | FIELD: medicine. n SUBSTANCE: method involves applying basic therapy until stroke type is unclear and differentiated therapy after having determined stroke type. Recombinant interleukine-2-roncoleukine as subcutaneous injections at a dose of 500 000 MU into external surface of intact arm at the fourth-fifth day after stroke beginning. Roncoleukine is administered as a course of 1-3 injections given with two-three days pause on the background of traditional stroke treatment. n EFFECT: enhanced effectiveness of treatment. n 2 cl, 3 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2464013-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2571282-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563123-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2629813-C1 |
| priorityDate | 2005-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 186.